


Facing Forward: Securing a Healthy Africa with Vaccine Manufacturing
2022 EAPD-IVI Online Vaccine Symposium



**2022 EAPD-IVI
Online Vaccine Symposium**

Facing Forward:
Securing a Healthy Africa
with Vaccine Manufacturing

Date June 7, 2022
Time 8:00-10:00 am GMT
10:00 am-12:00 pm (Cairo)
5:00-7:00 pm (Seoul)

The banner features a dark blue background with a world map and several circular icons depicting scientists in lab coats working in a laboratory. Logos for the 25th anniversary of the WHO, the International Vaccine Institute (IVI), the Ministry of Health of Ethiopia, and the EAPD (Ethiopian Agency for Partnership for Development) are displayed at the bottom.

Speakers (in order of appearance in the webinar program)



Birkneh T. Tadesse, M.D., Ph.D., Senior Research Scientist,
International Vaccine Institute

Dr. Tadesse is Senior Research Scientist at the International Vaccine Institute (IVI), Adjunct Associate Professor at Hawassa University, Ethiopia, and Affiliated Researcher at the Karolinska Institute, Sweden. He has more than a decade experience working in resource-limited settings in both patient care and clinical research. He earned his MD from the University of Gondar in Ethiopia, then did Pediatric residency at Addis Ababa University in Ethiopia. He completed his PhD in Medical Sciences focusing on Pediatric Infectious Diseases Epidemiology, particularly pediatric HIV, at the Karolinska Institute in Sweden. He joined IVI in 2019 and his main areas of research include vaccine development, vaccine effectiveness evaluation in field trials, post licensure safety evaluation and assessment of vaccine impact in developing

countries. He also heads the Vaccine Effectiveness Department and leads teams implementing large epidemiological studies estimating disease burden, vaccine development and impact evaluation projects in several LMICs.



Jerome H. Kim, M.D., Director General, International Vaccine Institute

An international expert on the development and evaluation of vaccines and is the Director General of the International Vaccine Institute (IVI), whose mission is to discover, develop and deliver safe, effective and affordable vaccines for Global Health. IVI's oral cholera vaccine is used around the world to prevent this deadly diarrheal disease. IVI's typhoid conjugate vaccine, tech-transferred to SK bioscience and PT Bio Farma; it was recently approved by the Korean Ministry of Food and Drug Safety. Dr. Kim is a Distinguished Visiting Professor, Seoul National University and an Adjunct Professor, Department of Medicine, Uniformed Services University and at the Graduate School of Public Health, Yonsei University. He has authored over 300 publications. He is a graduate of the University of Hawaii with High Honors in History and Highest Honors in Biology and received his M.D. from the Yale University School of Medicine. Dr. Kim has received the John Maher Award for Research Excellence, USUHS, 2013; Department of the Army Research and Development Achievement Award for Technical Excellence, 2013; Asia Pacific Vaccine Excellence Lifetime Achievement Award, 2021; and the Korean Medal of Honor for Civil Merit, 2022.



Mohamed Khalil, Secretary General, Egyptian Agency of Partnership for Development, Egyptian Ministry of Foreign Affairs

Ambassador Khalil began his career as an Egyptian diplomat at several different Egyptian Embassies and Consulates in different geographical areas (Japan, Algeria, South Africa and USA). In addition, he was the chief of mission of the Egyptian Embassy in Albania and before that, he worked as the Egyptian General Consul in Port Sudan. His diverse diplomatic expertise lets him to be a main player in the Egyptian South-South Cooperation file as being nowadays the Secretary General of the Egyptian Agency of Partnership for Development (EAPD) at the Egyptian Ministry of Foreign Affairs.



Dr. Kangho LEE, Deputy Minister for Global Vaccine Hub Office in the Ministry of Health and Welfare of ROK

Kangho has worked for 29 years in the Korean government and he has managed several policy areas such as vaccine policies including manufacturing, global partnership and hub etc., population policy, social service policy, child policy, international relations, and budget management.

He is currently the Deputy Minister for the Global Vaccine Hub Office in the Ministry of Health and Welfare (MOHW). He also served as the Director General (DG) of Health Industry Bureau where he developed bio-health industry development programs and development of pharmaceuticals and vaccines. He served as the DG of the Social Service Policy Bureau at the MOHW where he managed social service policies such as care services for the aged and the disabled. He also revised Korea's five-year plan related to low fertility and aging demographics and managed the introduction of the child allowance, with a budget of 3 trillion KRW (3 billion USD) and 2.4 million recipient children.

He is the co-chair of the Executive Committee of the Global Biomanufacturing Workforce Training Hub which is dedicated to empowering LMICs with self-sufficient vaccine production capacity by providing trainings for manufacturing vaccines & biopharmaceuticals. He had launched and served as the co-chair of the Steering Committee of the Public Expenditure Management Network in Asia (PEMNA) for two and half years, which has 13 member states. He also initiated the PEMNA secretariat in Seoul.

He negotiated with the WB, ADB, AfDB, IDB, and UNFPA concerning issues such as the management of the Korea Trust Fund, capital replenishment, annual meetings, and conferences. He has also served as the Vice Spokesman for over 200 correspondents. He was the director of Performance Management and Feasibility Studies in the Ministry of Economy and Finance (MOEF).

Kangho earned his Ph.D. in public administration and B.A. in economics from Seoul National University, and M.A. in public administration from the Kennedy School of Government at Harvard University.



Nicaise Ndembi, MSc, Ph.D., Senior Science Adviser, Africa Centers for Disease Control and Prevention

Dr. Ndembi is Senior Science Adviser at the Africa Centers for Disease Control and Prevention and Adjunct Associate Professor, Division of Epidemiology and Prevention at the Institute of Human Virology, University of Maryland School of Medicine, USA. He serves as Collaborative Professor of Virology in the Department of Viral Infection and International Health, Graduate School of Medical Science, Kanazawa University, Japan. and a Research Professor, Global Affairs Section at the same university.

He has actively participated in several scientific advisory panels and as an advisor to Nigeria's Federal Ministry of Health on HIV drug resistance and control policy. He is a member of the PharmAccess Technical Advisory Board for the Pan-African Study for Evaluation of Resistance (PASER) in Africa (Lancet Infectious Diseases 2012), and a member of the WHO Resistance Network Technical Working Group on Guidelines Development (Lancet 2012).

Dr. Ndembi is a graduate of Kanazawa University School of Medicine, Department of Viral Infection and International Public Health.




Ravi Ganapathy, Ph.D., Director CMC R&D, Hilleman Laboratories Singapore Pte. Ltd.

Dr. Ganapathy has more than 28 years of professional work experience in the hospital, biotech research & vaccine industry. He has hands-on experience in development, manufacturing, and testing of recombinant (bacterial/yeast-derived), bacterial and viral vaccines. Having led R&D, Production and Quality Assurance teams he has an extensive understanding of manufacturing and R&D-related quality & regulatory requirements for commercialization of biotech products, especially vaccines, and the related GLP & GMP documentation. He is currently the Director of CMC R&D at Hilleman Laboratories Singapore Pte. Ltd. Prior to joining Hilleman, he was the Head of Vaccine Development Department at IVI from May

2019 to April 2022, responsible for Vaccine Process Development division of the Science Unit.

Immediately prior to joining IVI he was with Biological E. Ltd., Hyderabad, India for over 5 years. While there he helped set-up laboratories, built and led the Manufacturing Sciences team providing full-fledged support to the commercial manufacturing divisions (production & QC) -including Life-Cycle Management involving the introduction of new delivery systems, and technology transfers. Based on the work done under his leadership at BE, two international patents have been filed; one involving a novel adjuvant preparation process (published), and the other pertaining to an alcohol-free polysaccharide purification process (currently under review).

Dr. Ganapathy graduated as a double-gold medalist for his post-grad work in 'Medical Entomology' from VCRC (ICMR) in 1993. Prior to that, he obtained his bachelor's degree in 'Medical Laboratory Technology' from JIPMER (1991). He has been a lead- or co-author of 8 research papers and has delivered talks at several international conferences.



Tarun Saluja, M.D., Clinical Research Scientist, International Vaccine Institute

Dr. Saluja is Clinical Research Scientist at the International Vaccine Institute, working as technical lead for typhoid conjugate vaccine as current assignment. He is a clinical research professional with experience in epidemiology studies, pre-clinical research and clinical experience in vaccine trials (Phase I-IV). His experience includes working on rotavirus, cholera, typhoid conjugate and dengue vaccines as clinical team lead.



Delese Mimi Darko, Chief Executive Officer, Food and Drugs Authority, Ghana

Mrs. Delese Mimi Darko graduated with a Bachelor of Pharmacy from the Kwame Nkrumah University of Science and Technology (KNUST) and a postgraduate master's degree in Business Administration from the University of Northampton. Her over 30-year career encompasses the regulation of food and drugs including clinical trials regulation,

marketing authorization and post approval, safety monitoring of medicines (allopathic and herbal), cosmetics, household chemicals and medical devices.

She has risen through the ranks of the Food and Drugs Authority (FDA) to become the first female Chief Executive Officer since 2017.

She was instrumental in designating the FDA as a Regional Center of Regulatory Excellence in 3 critical areas, namely, Medicines Safety (pharmacovigilance), Clinical Trials, and Drug Registration by the NEPAD/African Medicines Regulation Harmonization (AMRH).

Mimi chairs both WHO African Vaccines Regulatory Forum (AVAREF) and the West African Medicines Regulatory Harmonization Steering Committees. She also serves on several international and local advisory committees and bodies.

Her exemplary and commendable work has earned her several awards. Notable amongst them are the United Nations (UN) Inter-Agency Task Force (UNIATF) award on the Prevention and Control of Non-Communicable Diseases in New York, the GLITZ Africa's award for Ghana Women of the Year Honours 2019 (Excellence in Health), Ghana Business Standard Awards for the Female Business Leader of the Year 2019 and the Advertising Association of Ghana Special Recognition award for her role in regulating the advertisement of FDA regulated products.

Mimi is a devout Christian and is married with two children.



Kaja Abbas, Ph.D., Assistant Professor of Disease Modelling,
London School of Hygiene and Tropical Medicine

Dr. Abbas researches vaccine impact modelling with a focus on estimating the health, economic, and equity impact of vaccination programmes at the global, regional, and national levels. He has worked on impact assessment of different vaccines, including human papillomavirus, measles, Haemophilus influenzae type b, rotavirus, pneumococcal, influenza, dengue, Strep A, typhoid, COVID-19, and basic vaccines in the childhood immunisation schedule, in varied settings of low-, middle-, and high-income countries.



Youngmee Jee, M.D., Ph.D., Chief Executive Officer, Institut Pasteur Korea

Dr. Youngmee Jee (M.D., Ph.D.) is Chief Executive Officer of the Institut Pasteur Korea and also serves as Special Representative for Health Diplomacy, Korea Foundation. Dr. Jee has broad experience in collaborating with WHO and international public health partners.

Currently, Dr. Jee is a member of the WHO International Health Regulation Emergency Committee on COVID-19 and of the WHO Scientific Advisory Group for the Blueprint on Research and Development Preparedness for Epidemics.

Dr. Jee worked as Regional Laboratory Coordinator in the Expanded Programme on Immunization of the WHO Western Pacific Regional Office (WPRO) during 2007-2014 to coordinate national and regional public health institutes in over 20 countries in the region. From 2014 to 2019, Dr. Jee served as Director-General of the Center for Infectious Disease Research of the KCDC. Dr. Jee received a President Medal of Distinguished Service in 2017.

Dr. Jee received her M.D. from the College of Medicine, Seoul National University, a Diploma in Medical Microbiology from the London School of Hygiene Tropical Medicine, and her Ph.D. from the University of London.



Duncan Steele, Ph.D., Deputy Director, Global Health, Bill & Melinda Gates Foundation

Dr. Steele is a microbiologist with extensive experience in virology and microbiology, especially for diarrhoeal diseases, and in clinical trials. His current responsibilities include strategic leadership and oversight of the portfolio of vaccines against the major enteric and diarrheal diseases at the Bill & Melinda Gates Foundation (i.e. rotavirus, cholera, enteric fever, and *Shigella*).

Previously, Dr. Steele worked across both Vaccine Access and Delivery (VAD) within the Rotavirus Vaccine Program and in Vaccine Development (VAC) with the Advancing Rotavirus Vaccines program and the Enteric Vaccines Initiative at PATH.


As a scientist at the Initiative for Vaccine Research, Department of Immunization, Vaccines and Biologicals, World Health Organization, Dr. Steele was responsible for the diarrheal

disease vaccines portfolio. In this role, he developed and coordinated a global strategic agenda for vaccine research for the major diarrheal and enteric diseases including cholera, enterotoxigenic *E coli*, rotavirus, *Shigella*, and typhoid fever. In addition, he coordinated and facilitated vaccine clinical trials in Africa and Asia and established, coordinated, and facilitated regional surveillance networks in Africa, the Middle East, and Eastern Europe in collaboration with the WHO Regional Offices, ministries of health, PATH, and CDC.



Nakorn Prensri, M.D., Director, National Vaccine Institute, Thailand

Dr. Prensri is the Director of the National Vaccine Institute, Thailand, appointed in February 2019. He has had extensive experience in health promotion, disease prevention and control and public health program management. Dr. Nakorn completed his medical training from the Faculty of Medicine, Chulalongkorn University, Thailand in 1993 and started his career at the Ministry of Public Health, as the director of a district hospital in 1993-1996. He became the Chief of Social Medicine Department at Sakaew Crown Prince Provincial Hospital in 1998, after completing the Field Epidemiology Training Program (FETP) at the Division of Epidemiology, Ministry of Public Health in 1996 -1998. In 2003 he worked as a research investigator in the world's largest HIV Vaccine Phase III trial (RV144, Thai Trial) and became the Director of Principal Recipient Office for the Global Fund to Fight Against AIDS, TB and Malaria (GFATM) in 2009, before being appointed the Director of Bureau of Epidemiology, Department of Disease Control in 2017.



Agnès Buzyn, M.D., Ph.D., Executive Director, World Health Organization Academy

Professor Buzyn served as the French Minister of Solidarity and Health from 2017 to 2020. In 2016, she was appointed Chairman of the French Authority for Health (HAS) in charge of notably Health Technology Assessment. Between 2011 and 2016, Professor Buzyn served as the Executive President of the French National Cancer Institute (INCa). During that mandate, she wrote and implemented the national cancer control plan 2014-2019. In the same period, she represented the French government at the governing council of the International Agency for Research on Cancer (IARC) and in 2015 was elected Vice-President of the IARC. From 2008 to 2013, Professor Buzyn chaired the Executive Board of the French

Radioprotection and Nuclear Safety Institute (IRSN).

Agnès Buzyn was a Professor of Hematology at the University Pierre-and-Marie-Curie in Paris. She spent a large part of her career as an academic hematologist and clinician at the University Paris Descartes Necker Hospital, where she was in charge, between 1992 and 2011, of the adult hematology intensive care and bone marrow transplants unit. Before that, starting back in 1995, she carried out research at the National Institute of Health and Medical Research (INSERM) where she headed a team on tumor immunology. Professor Buzyn also served as faculty professor at that hospital. She received an M.D. from University Pierre-and-Marie-Curie in Paris and a Ph.D. in immunology from the University Paris Descartes.



Patrick Tippoo, Head of Science and Innovation, Biovac and Executive Director, African Vaccine Manufacturing Initiative (AVMI)

Mr. Patrick Tippoo is Head of Science and Innovation at Biovac, where he leads vaccine product development. He is a founding member and the current Executive Director of the African Vaccine Manufacturing Initiative (AVMI), advocating for the establishment of vaccine development and manufacturing capacity in Africa. He continues to champion AVMI's engagement with the Africa CDC-led Partnership for African Vaccine Manufacture (PAVM) in the development of the Framework For Action, a ground-breaking continental initiative to ensure that Africa has the necessary capacity to produce routine and pandemic vaccines. He serves as Vice President of the Developing Country Vaccine Manufacturers Network (DCVMN) and is on the board of the recently formed Emerging BioPharmaceuticals Manufacturing Network (EBPMN).



Heba Wali, Ph.D., VACSERA Chairman, Holding Company of Biological Products and Vaccines

In her capacity as "VACSERA Chairman" since 2018, Dr. Wali has successfully contributed to provision of wide range of health services to Egyptian. The services portfolio includes but not limited to, securing continuous supply of national requirements of vaccines & sera which locally produced in compliance with National Health Plan, as well great experience in technology transfer field in vaccine industry and recently with successes contribution in coronavirus disease (covid-19) pandemic with the production of millions of

doses of COVID vaccine through technology transfer agreement for securing the national needs, with future plan for considering VACSERA as one of the HUB plant for vaccines production for securing African countries' needs.

Dr. Wali has successfully contributed to leading growth within VACSERA and related affiliated companies through her balanced strategic decisions that led to overall improvement in organizational performance. During a fruitful journey of varied working experience, Dr. Wali held multiple managerial positions, she started her managerial tenure in 2006 as "Project Manager" in ENRA (Egyptian National Regulatory Authority) for 5 years which is ended by ENRA recognition by WHO (World Health Organization) in October 2010. In 2011.

All of previous positions together with acting as "WHO Consultant" for 2 years and an efficient history in both quality & regulatory fields enabled Dr. Wali to work in a challenging and dynamic environment. Dr. Wali is an Egyptian national, with "PhD" degree, Masters of Business Administration "MBA", Diploma in TQM and Certified Project Manager (Internal Federation of Project Management, Switzerland).